PharmaTalkRadio

Tapping into research-naïve sites offers a strategic opportunity to expand patient access. That’s exactly what Endo did when faced with challenges activating sites for their orthopedic study. This case study shares how Endo enabled a new site through hands-on mentorship, infrastructure support, and trust-building— resulting in sustainable partnerships and broader patient reach.How naïve sites can help address access and enrollment bottlenecksHow to support inexperienced sites with the right sponsor-led infrastructureWhat it takes to shift internal expectations and foster lasting site partnershipsSpeakers:Carrie Lewis Executive Director, Clinical Program Optimization, EndoSuzy Montayne Site Relationship Manager, EndoTerry Oehler, DPM Founder & CEO, Colorado Clinical Research

AstraZeneca’s US Site Engagement Leads will share how they are reimagining sponsor-site relationships through a trust-first, high-engagement operating model that emphasizes flexibility, responsiveness, and co-creation. This session will showcase how their embedded approach to collaboration has enabled faster site activation, stronger recruitment performance, and improved data delivery—backed by real metrics and lessons learned from a three-year initiative. Key topics include:How continuous site feedback loops and flexibility with SOPs improved startup timelinesMetrics from a recent study showing impact: 30% faster budget negotiations, 27% reduced activation times, 68% of recruitment from 42% of sitesTools and tactics used to build consistency, transparency, and trust across studiesLessons learned and how the program has scaled globallySpeakers:Shannon Edwards Site Engagement Lead, AstraZenecaTina Nghiem Site Engagement Lead, AstraZeneca

A case study highlighting how Eli Lilly partnered with clinical sites to co-design practical, site-centric solutions that enhanced trial execution and operational efficiency.Fireside Guest: Shafaat Ali Khan Clinical Research Lead (CRL) Director – Investigator Engagement, Eli Lilly & CoModerator: Jyoti Angal, PhD Director, Clinical Research, Avera McKennan Hospital & University Health Center

This case study highlights how Basil Clinical Research and Takeda’s first-time partnership became the top global recruiter, exceeding enrollment goals by tenfold through proactive assessments, early collaboration, and inclusive design. Learn how Takeda’s shift from transactional to strategic, long-term partnerships made this success possible.Identifying and partnering with highpotential sitesIncorporating site feedback and early collaboration to improve trial executionBuilding trust and fostering long-term site relationshipsKey actions that led to exceptional enrollment and trial efficiencySpeakers:Brandon Doyle, MBA Associate Director, Study Site Engagement, Takeda Mark Rapp, MD Principal Investigator, Basil Clinical Research

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts address: Integrating connectivity into drug delivery devices as a way to improve patient engagement and adherenceHow pharma can use drug delivery device data with predictive analytics to forecast demand and optimize productionEnabling patient-centric design and innovation by analyzing device usage dataTo learn more about the PODD Conference, please visit PODDConference.com.

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts address how the biopharma and drug delivery industries actively move to embed sustainability into core principles, products and processes. Specifically:How pharma and suppliers can improve sustainabilityCreating designs with lower carbon footprints relative to fabrication and materialsCircular recycling modelsTo learn more about the PODD Conference, please visit PODDConference.com.

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives discuss specific examples of AI/ML usage by pharma companies through the combination product development process from iteration to commercialization as well as a discussion on how this field will evolve in the coming years.To learn more about the PODD Conference, please visit PODDConference.com.

Manufacturing scaleup is a key hurdle in enabling the efficacy of new device technologies. Often this requires a mix of internal and external manufacturing and implementing a commercial control strategy across partners.In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma and CDMO executives discuss effective partnering between pharma and manufacturing as well as growing pains and lessons learned in scaling.To learn more about the PODD Conference, please visit PODDConference.com.

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts discuss progess in the development of liquid/liquid and liquid/lyo dual chamber systems. Specifically, they address: Overcoming primary container and autoinjector challenges for liquid-liquid deliveryImproving upon dual chamber reconstitution devicesFinding the right approach to navigate supply chainTo learn more about the PODD Conference, please visit PODDConference.com.

About this Podcast: As pharma sponsors continually assesses how to integrate AI into their ways of working, Evinova’s Chief Technology Officer, Sean Connolly, talks about where, how, and when AI is actually making an impact on clinical development based on insights and experiences of working with pharma.Sean share his thoughts on going for low hanging fruit to encourage adoption, what he's seen in terms of pharma companies that are successfully implementing AI across their enterprise, and how he would recommend organizations that are just starting out on their AI journey assess their individual needs and priorities when it comes to AI.More specifically, Sean discusses:  Separating short-term, mid-term and long-term costs and benefits of implementing AI What business leaders at JP Morgan Health 2026 were saying about how they view the value of AI AI deployed for bottom-line revenue versus internal team efficiency What the first steps would be for sponsors to successfully integrate AI across their enterprise 

About this podcast:Recorded at DPHARM 2025, Bayer's Dr Bernhard Glombitza reports on the development, implementation and early impact of their clinical operations reorgnization. He describes how shifting from a traditional hierarchical model to a network of highly empowered teams reduced management layers, broadening the scope of work and changed cross-country operations monitoring. Dr Glombitza details the results of the change thus far, including significant increases in efficiency and reduction in cost, maintaining quality levels and study targets, and improving employee job satisfaction. 

About this podcast:In this keynote from Patients as Partners in Clinical Research 2025, Amicus Therapeutics' Chief Patient Advocate, Jayne Gershkowitz, shares how their organization established and embedded patient advocacy into their core structure for lasting impact.More specifically, Ms Gershkowitz focuses on:Defining role standards and recruiting the right talent Co-creatin research with patient communities and developing patient-centered outcomesGenerating metrics that demonstrate the impact on R&D

When designing clinical trials, CMOs aim to answer meaningful questions for a plethora of stakeholders. Inherently, this results in study protocols with more measures, biomarkers and data collection that both provides a platform for strategic decision-making but also impacts patient burden, operational foot-print, timelines and cost. In this panel discussion from the 2025 Chief Medical Officer Summit 360°, CMOs address how to develop a balanced strategy that takes into account the ambition to answer these questions with the realities of complicated clinical trials.More specifically:Prioritizing data collection strategy to answer key scientific questions while avoiding overcomplicationDesigning trials around real patients rather than ideal patientsBetter understanding the objectives of the study and asking the questions that achieve those objectivesBetter partnering with patients and PIsTo learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.

Investing in developing a durable platform and strategy early leads to fewer delays throughout development. Locking requirements in early and educating teams to approach combination product development holistically lowers the time to development dramatically. In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts discuss how they used platform devices in concert with an internal engagement strategy to speed up development. Specifically, they address: Advantages and disadvantages to platform approaches for device developmentOpportunities to overcome technical limitationsApproaches to bring a platform into multiple product design history filesRegulatory hurdlesAssessing business case and getting organizational buy-inTo learn more about the PODD Conference, please visit Drug-Delivery.org.

About this podcast:Recorded at the 2025 DPHARM conference, this state of the union panel convenes site, technology and pharma to discuss: Different models and the pros and cons of the deployment modelsWhat makes a great patient matching solutionPredicting what the future growth of this segment looks likeThe role of AI in this space

About this podcast: Recorded at the 2025 IO360º Summit, this podcast addresses how Project Optimus is reshaping dose selection from maximum tolerated dose to a balance of efficacy and safety. More specifically, this panel addresses FDA objectives for multi-dose selection, alternative dose-selection strategies with imaging, biomarkers and tumor burden analysis, the higher costs and longer timelines, and financial impacts for early-phase oncology companies. For more information, go to IO360summit.com.

About this podcast: Recorded at the 2025 CRAACO meeting, UNC Lineberger’s Comprehensive Cancer Center shares  an initiative to allow local HCPs to still provide clinical care to patients but decentralized research elements to the university system, following the FDA’s change in guidance on Form FDA 1572, which stopped requiring local healthcare professionals (HCPs) involved in DCTs to be listed if they’re only performing standard-of-care. Dr J Kaitlin Morrison talks about the process from an initial pilot of two sites to more than 23 today, providing cancer patients across the state the opportunity to access clinical trials. Specifically:How they are managing relationships with sitesHow they’re monitoring research elementsGoals, next steps and thoughts for industry sponsors

About this podcast:This podcast, recorded at the 2025 Patients as Partners Europe meeting, addresses how Novo Nordisk is consolidating patient insights to ensure greater knowledge-sharing, data integrity and traceability, addressing the unmet needs of patients, aligning product outcomes with patient expectations, and more. For more information, go to theconferenceforum.org. 

In this podcast, Kate Woda, Conference Director of the Patients as Partners in Clinical Research conference discusses what attendees can expect at the 13th annual event, including key topic areas, session highlights, presenting companies and more. For more information about the upcoming event, full agenda and speakers, visit patientsaspartnersconference.com.

In this podcast, featuring a panel discussion from the 2025 Chief Medical Officer Summit 360°, CMOs with recent M&A and partnership experience share those experiences as well as how CMOs of other small to midsize emerging biotech companies can support the conversations and operations that take place throughout the process of business development. Specifically:Different kinds of BD deals to be aware ofHow the CMO fits into various phases of transactionsAppreciating how different c-suite colleagues and direct reports experience these transactionsThe different pharma teams CMOs will interact withWhat happens after the acquisitionTo learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts discuss conjugation and bioconjugation approaches to make ASOs and small molecules more tolerable while improving targeting. Technologies discussed include ADCs, PDCs, SMDCs, VDCs, RDCs and AOCs. Specifically they address:Biological and chemical challenges for these therapiesBuilding out scalable manufacturing and a regulatory strategyHurdles to overcome to get products to marketTo learn more about the PODD Conference, please visit Drug-Delivery.org.

This podcast features a panel discussion from the 2025 Chief Medical Officer Summit 360° about how to strategically approach hiring FTEs, insourcing, outsourcing and contracting to be appropriately prepared for the different stages of a biotech companies development from preclinical to early stage to late stage trials to commercialization. Specifically:Balancing the mix of hires and outsourcingHiring for skillsets to enable efficiency without overhiringReactive vs proactive hiringBuilding in a stage appropriate way but also hiring in time for later stagesTo learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.

While lipid nanoparticles are the most clinically advanced drug delivery system for nucleic acid therapeutics, they are only one tool in a toolbox of potential delivery vehicles.In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts discuss additional tools, including polymeric nanoparticles, protein-based nanoparticles and extracellular vesicles with a focus on:Where LNPs potentially fall shortWhere different tools can enable therapeutic deliveryChallenges to achieving meaningful clinical impact for these different vehiclesBuilding out a portfolio of delivery vehiclesTo learn more about the PODD Conference, please visit Drug-Delivery.org.

About this podcast: This podcast comes from the DPHARM 2025 meeting. Pfizer details how they jointly co-designed and implemented an EDC/CDMS platform that’s fit for purpose, and analysis data set. This session focuses on:Engaging all stakeholders in designing the platformThe evolution of the platform focus: the transition from the majority of data coming from EDC to 3/4 of the data from third party sourcesImpact of the advanced data analysis capabilities for risk managementReview of impact on initial studies now using the platform For more information, go to DPHARMconference.com. 

About this podcast: Preliminary survey results conducted by the Tufts CSDD focus on the strategic and structural growth of new trial sites and partnerships in bringing trials directly to the local communities. The preliminary survey findings also shed light on the strategic and structural growth of these new trial sites and partnerships, offering valuable insights into the evolving global clinical trial landscape.The significant shift towards bringing clinical trials directly to local communities through various innovative models is noteworthy. Many new clinical trial execution models have been introduced during the past decade including site staff embedded within clinical care settings, remote sites, retail pharmacies, urgent care facilities, and mobile units going directly into local communities. This session comes from the 2025 Partnerships with Sites Summit. 

About this podcast:This session, from the 2025 IO360 Summit, focuses on different strategies to augment immune response in urothelial carcinoma, presented by Dr Jonathan Rosenberg, Memorial Sloan Kettering Cancer Center. Dr Rosenberg focuses on: The background and previous data of immune checkpoint blockade as monotherapy and in combination with chemotherapy, in urothelial cancerThe potential role of Immunogenic Cell Death and whether it has a clinical impact on patient care and creating an anti-tumor immune responseEnfortumab vedotin, an ADC targeting Nectin-4For more information, go to IO360summit.com.

About this podcast:This presentation from the 2025 IO360º Summit focuses on the immunological effects of radiopharmaceuticals, presented by Chaitanya Divgi, Sr Strategic Expert, Therapeutic Innovation, at Novartis. Specifically, this podcast dives deeper into: An introduction to radioligand therapyA focus on PSMA-targeted radionuclide therapyPrelimary work on the relationship between systemic radiation therapy and immune effects at the tumor level For more information, visit IO360summit.com 

About this episode:In this podcast, Dr Penny Heaton, Global Head of the Johnson and Johnson Office of the Chief Medical Officer, discusses: J&J’s approach to patient centricity across the enterpriseHer thoughts on balancing balancing safety and risk/benefit ratios with more engaged patients and more complex scienceMoving risk benefit assessments earlier into clinical development and the necessary change managementIncorporating multiple streams of data for the purpose of creating medicines that truly address patient needs in the real worldFor more information, go to PatientsasPartnersConference.com. 

In this podcast, Nicole Murphy, EVP and Head of Pharmaceutical Operations & Technology at Biogen, discusses:Cross-functional collaboration to deliver valueHow Biogen is using AI to enhance innovationSupply chain simplificationBiogen's partnership philosophy as it relates to drug deliveryTheir recent $2 billion manufacturing investment in the Research Triangle ParkAnd Biogen's acquisition of Alcyone Therapeutics It's an enlightening look into what real leadership in drug delivery, manufacturing and supply chain management looks like. For more information, go to Drug-Delivery.org.

In this podcast, Kate Woda, Conference Director of the Immuno-Oncology 360° Summit, discusses what attendees can expect at the 12th annual event, including key topic areas, session highlights, presenting companies and more.For more information about the upcoming event, full agenda and speakers, visit IO360Summit.com.  

This podcast features a panel discussion from the 2025 Chief Medical Officer Summit 360° with CMOs and advisory solutions firms about how CMOs can work with consultants and fractional talent to stay on budget while getting the expertise needed. Specifically:Different profiles of fractional consultantsWhat to look for in a consultant and how to ensure alignment with the teamScoping the role of fractional talent and iterating as company needs evolveHow to best work with firms representing fractional talentAdvice for CMOs thinking about consultingTo learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.

About this podcast:This podcast dives deep into the fundamentals of antibody-drug conjugate design, specifically focusing on the selection of targeting antibodies, cytotoxic drugs, and linkers. Presenter Dr Deepa Pakianathan highlights key strategies for constructing ADCs and the critical differentiating features that enhance therapeutic efficacy and safety. For more information, go to IO360summit.com.

About this podcast:This podcast comes from the 2025 Patients as Partners in Clinical Research conference. This panel discussion demonstrates how patient advocates are bridging the divide at the site level to improve patient representation in clinical trials. More specifically, this podcast focuses on: Strategies for overcoming limited resources and lack of infrastructure, which can hinder inclusive clinical trial participationSuccessful models for empowering local leaders and leveraging community-based networks to increase participationEvaluating the impact of outreach and engagement efforts on enrollment representation and overall care equityAnd moreFor more information, go to PatientsAsPartnersConference.com.

About this podcast: Liz Thompson, Global Development Leader, Senior Clinical Development Scientist at Roche, presented how the organization had delivered a single, cohesive protocol amendment categorization process to reduce the number of amendments and create a continuous improvement strategy, all to speed up timelines and reduce costs. This presentation comes from the September 2025 DPHARM: Disruptive Innovations to Modernize Clinical Research program. More specifically, Ms Thompson discusses how Roche is: Leveraging historical amendment data to enable study teams to understand why protocols are being amendedUtilizing a visual data science platform to generate insights from data to make better data-driven decisionsApplying retrospective learning into current protocols to curb the need for amendmentsBuilding in business value For more information, go to DPHARMconference.com.

About this podcast:This session was recorded at the September 2025 CRAACO: Clinical Research as a Care Option conference.Rural sites represent untapped potential for reaching a broader array of patients and providing them access to life-changing clinical trials, but existing clinical trial infrastructure does not set rural sites up for success. Funded through the Genentech Innovation Fund, Montana State University and Billings Clinic created a rural clinical research readiness toolkit for unaffiliated rural and frontier healthcare systems to empower them to meet clinical research demands without compromising local care delivery.More specifically, this presentation covers the tools created to toolkit empowers sites to do clinical research, including:Interpretable workflow templatesA workload calculator for staff capacity planningPatient safety indicators to support enrollment and retentionEHR-based visualization methods to assist clinical decision-making when trial participants are also patientsAnd moreFor more information, go to theconferenceforum.org.

This podcast features a panel discussion from the 2025 Chief Medical Officer Summit 360° with biotech CMOs about how CMOs can support value creation in biotechs and how that is influenced buy the current biotech financial climate. Specifically:The importance of storytelling and leading thoughtfullyEffective prioritization and execution towards the company narrativeBalancing the team to be lean while avoiding the potential pitfalls of running leanBalancing the data collected to be interesting to investigators and important for the program to proceedClinical data generation is better than preclinical dreamsStrategically choosing a first indication and building sufficient scientific bridging to support subsequent indicationsTo learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.

In this podcast from the DPHARM 2024 archives, Biogen discussed how they used an AI-enabled software to detect cognitive impairment and Alzheimer’s disease neuropathology, based on voice, to provide access to patients  with a clinically validated cognitive assessment who might not otherwise have the foundation to start a conversation with their physician about their cognition. For more information, go to DPHARMconference.com

At the March 2025 Patients as Partners conference, Merck presents how they advancing patient and community engagement through targeted initiatives designed to improve trial participation, relevance, and long-term impact. Key topics include:Identifying and addressing patient and community needsStrategies for earning trust and fostering sustained engagementKey collaborations and partnerships driving meaningful changeApproaches to developing patient-centered endpoints and outcomesMethods for effectively communicating and disseminating trial resultsFor more information, go to PatientsAsPartnersConference.com

Summary: This session was recorded at the March 2025 Patients as Partners conference. In this session, Pfizer addressed how they were working to ensure continuity in the patient insights they were collecting, throughout the product life cycle. This included: Approaches for aligning internal processes to facilitate the seamless flow of patient insights from early-phase to late-phase teamsSuggested tools, including an AI Insights tool designed to centralize and leverage previous patient feedback, supporting a more integrated approach to patient engagementStrategies to build on existing insights, enhance collaboration across teams, and drive more effective patient-centered outcomes in R&D processesFor more information, go to PatientsAsPartnersConference.com.

Summary: From the DPHARM Archives, this podcast was recorded at the September 2024 DPHARM conference. In this podcast, BMS present how they specifically targeted the challenge of recruiting patients for clinical trials, aiming to make the process faster and easier. By bringing trials directly to patients, their ultimate objective was to significantly expedite patient enrollment. In this case example, they brought the audience through their new product model approach, for the organization's overarching goal of reducing the drug timeline from discovery to launch by three years.

About this podcast:Recorded at the 2025 Immuno-Oncology 360º Summit, Stanford University's Dr Crystal Mackall shares work from her lab developing GD2-targeting CAR T cell therapy for the treatment of deadly pediatric brain tumor, as well as broader lessons on the evolution of cell therapy, and her forward-looking perspective on shaping the next generation of cancer treatments.For more information, go to IO360summit.com. 

Summary:Rescuing a clinical trial and choosing to switch vendor's mid-trial are some of the most expensive decisions biotech CMOs can make. These rescues require a significant amount of time, money and energy and may not even address the root issue behind a trial's poor performance. In this podcast, Raul Lima, SVP, Strategic Clinical Operations, inSeption Group, discusses a scaffolding approach that prioritizes areas that require immediate support without sacrificing the entirety of the trial. Specifically:How biotechs can better identify root causes of issues and correct themMistakes CMOs make when implementing rescuesWhen and how a scaffolding approach can be more resource, time and financially efficientFor more information about inSeption Group, visit inSeptionGroup.com. For more information about the annual Chief Medical Officer Summit 360° and its affiliated editorials, podcasts and webcasts, please visit CMO360.org.

Summary:When developing patient-centric products for biologics, different doses, expressed by different combinations of volume/concentration may require different delivery devices. As a result, it takes a great deal of time and effort in planning and coordinating the formulation and device activities. In this podcast, Pharma and Drug Delivery executives from Nanoform, Pfizer, GSK, Takeda and Kymanox discuss how they facilitate partnerships between drug product development, device engineering and clinical study teams to determine how to balance concentration and volume and develop optimal devices for delivery and commercialization. Specifically:Impact on increasing concentration of drugs on deliverabilityTechnical feasibility of manufacturing larger volume devicesPatient tolerability and human factors that impact patient adherenceThis panel discussion was recorded at the October 2024 PODD: Partnership Opportunities in Drug Delivery conference. For more information, go to Drug-Delivery.org.

In this podcast series, DPHARM Director Tracey Kimball with Valerie Bowling, Executive Director of the Conference Forum, break down what to expect at DPHARM 2025. Part III of this podcast series covers sessions addressing AI in Clinical Trials.

Summary:Accessibility to CAR-T is limited by traditional manufacturing, with its associated challenges and high cost. Moffitt Cancer Center's Chief BioEngineering Officer, Dr Greg Sawyer, highlights Moffitt's significant progress in enhancing T cell potency and boosting efficacy through engineering strategies. Dr Sawyer discusses assays enabling precise asessment of T cell potency, developments in manufacturing, and more, and the resulting impact on scalability and efficiency. This presentation comes from the March 2025 Immuno-Oncology 360º Summit. For more information, go to IO360summit.com. 

Summary:In this podcast, Pharma and Drug Delivery executives from Novartis, AstraZeneca, Merck and Quotient Sciences discuss traditional and novel approaches to improve the oral delivery of peptides including:The biopharmaceutics of oral peptide and the use of permeation enhancersAlternate sites for the delivery of oral peptides throughout the GI tractImproving oral exposure through ingestible devices Delivering ASOs and other large syntheticsNext-generation approaches for deliveryThis presentation was recorded at the October 2024 PODD: Partnership Opportunities in Drug Delivery conference. For more information, go to Drug-Delivery.org.

Summary: In this podcast, Dr Anthony Yanni, SVP, Head of Patient Centricity at Astellas, presented the business rationale for patient-centric medicine development, how it's disrupting the pharmaceutical industry and why companies have to act swiftly to remain competitive. Dr Yanni discusses how to align medicine development with healthcare delivery and the necessary cultural transformation that is critical to sustaining it, practical steps to incorporate patient input early into the R&D process, operationalizing patient-centric processes, methods to measure impact, and more.This presentation was recorded at the March 2025 Patients as Partners in Clinical Research conference. For more information, go to PatientsAsPartnersConference.com.

This podcast features a panel discussion from the 2025 Chief Medical Officer Summit 360° with biotech CMOs across indications about how CMOs can better develop drugs patients want and derisk development by partnering with patient organizations. Specifically, the panelists address:Patient voice driving drug development forwardSupporting health equity and patient access after approvalBuilding genuine relationships and engaging early to get to the right patients at the right time and for better advocacy about your researchBuilding a community of awareness and working with patients for support throughout the regulatory processIntegrating the patient perspective in earlyReal world examples and their impactsTo learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.

Summary:In this session, pharma sponsors and sites gather to present innovative solutions to solve site challenges in workforce and capability gaps, increasing technology burden, patient enrollment and managing clinical trial protocol complexity. They discuss efforts to address those challenges, early impacts and outcomes. In this panel: Dennis Salotti, MS, MBA, Executive Director & Head of Clinical Outsourcing & Innovation, Jazz PharmaceuticalsKristin Herman, Executive Director, Clinical Trials Office, Sidney Kimmel Cancer Center, Jefferson HealthEileen Hughes, RN, BS, Senior Manager, Site Partnerships, CSL BehringLisa Kiehne, SVP, Operations, The START Center for Cancer Research Christopher McNair, PhD, Associate Director, Data Science and Cancer Informatics, Sidney Kimmel Cancer Center, Jefferson HealthTracey Robertson, Head of Patient and Site Engagement Capability Management, Boehringer Ingelheim This panel was recorded at the 2024 DPHARM: Disruptive Innovations to Advance Clinical Research. For more information about the 2025 DPHARM, visit DPHARMconference.com. 

Conference Forum Director Valerie Bowling and CRAACO Producer Danny McCarthy break down what to expect at the 2025 CRAACO program. This podcast covers the keynotes, panels and key themes for this year's event, including: How to develop a clinical research program within a community cancer center, with Dr Brian Slomovitz, Mount Sinai Medical Center Miami BeachTurning clinical environments into learning health systems, with Dr Laura Esserman, UCSF Carol Franc Buck Breast Cancer CenterHow to better partner with multiple location health system structures for clinical trials Addressing medical staff shortages and challenges to support clinical researchThe impact of clinical trial participation on cost and performance in cancer centersEHR and AI advancements for clinical research And more Want to know more about CRAACO? Visit CRAACOevent.com.